This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nissen, P. H. Articles by Mosekilde, L. Search for Related Content PubMed PubMed Citation Articles by Nissen, P. H. Articles by Mosekilde, L. Pubmed/NCBI databases Gene GEO Profiles HomoloGene OMIM Protein UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL PARATHYROID HORMONE Related Collections Calcium and Bone Metabolism

Molecular Genetic Analysis of the Calcium Sensing Receptor Gene in Patients Clinically Suspected to Have Familial Hypocalciuric Hypercalcemia: Phenotypic Variation and Mutation Spectrum in a Danish Population

Departments of Clinical Biochemistry (P.H.N., L.H.) and Endocrinology and Metabolism (S.E.C., L.M.), Aarhus University Hospital, Aarhus Sygehus, DK-8000 Aarhus C, Denmark; and Department of Endocrinology (K.B.), Odense University Hospital, DK-5000 Odense, Denmark

Address all correspondence and requests for reprints to: Peter H. Nissen, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus Sygehus, Tage Hansens gade 2, DK-8000 Aarhus C, Denmark. E-mail: sci08phn{at}as.aaa.dk.

Context: The autosomal dominantly inherited condition familial hypocalciuric hypercalcemia (FHH) is characterized by elevated plasma calcium levels, relative or absolute hypocalciuria, and normal to moderately elevated plasma PTH. The condition is difficult to distinguish clinically from primary hyperparathyroidism and is caused by inactivating mutations in the calcium sensing receptor (CASR) gene.

Objective: We sought to define the mutation spectrum of the CASR gene in a Danish FHH population and to establish genotype-phenotype relationships regarding the different mutations.

Design and Participants: A total of 213 subjects clinically suspected to have FHH, and 121 subjects enrolled as part of a family-screening program were studied. Genotype-phenotype relationships were established in 66 mutation-positive index patients and family members.

Main Outcome Measures: We determined CASR gene mutations, and correlating levels of plasma calcium (albumin corrected), ionized calcium (pH 7.4), and PTH were measured.

Results: We identified 22 different mutations in 39 FHH families. We evaluated data on circulating calcium and PTH for 11 different mutations, representing a spectrum of clinical phenotypes, ranging from calcium concentrations moderately above the upper reference limit, to calcium levels more than 20% above the upper reference limit. Furthermore, the mean plasma PTH concentration was within the normal range in eight of 11 studied mutations, but mild to moderately elevated in families with the mutations p.C582Y, p.C582F, and p.G553R.

Conclusions: The present data add 19 novel mutations to the catalog of inactivating CASR mutations and illustrate a variety of biochemical phenotypes in patients with the molecular genetic diagnosis FHH.

This article has been cited by other articles:

				S. E. Christensen, P. H Nissen, P. Vestergaard, L. Heickendorff, L. Rejnmark, K. Brixen, and L. Mosekilde Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism Eur. J. Endocrinol., December 1, 2008; 159(6): 719 - 727. [Abstract] [Full Text] [PDF]